Alkeon Capital Management
BEAM icon

Alkeon Capital Management’s Beam Therapeutics BEAM Stock Holding History

Alkeon Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-500,000
Closed -$40.8M – 177
2020
Q4 		$40.8M Hold
500,000
– – 0.07% 121
2020
Q3 		$12.3M Hold
500,000
– – 0.02% 127
2020
Q2 		$14M Hold
500,000
– – 0.04% 123
2020
Q1 		$9M Buy
+500,000
New +$10.9M 0.04% 115

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Alkeon Capital Management's BEAM Position: Q1 2021 in Review

Alkeon Capital Management sold out of Beam Therapeutics (BEAM) in Q1 2021, closing a stake of 500,000 shares — an estimated $40.8M sold.

Alkeon Capital Management first reported a position in BEAM in Q1 2020 and held it in 4 quarters. The position peaked at $40.8M in Q4 2020. 209 funds tracked by Wall St. Rank hold BEAM as of Q1 2021.

  • Alkeon Capital Management reported no remaining Beam Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Alkeon Capital Management sold 500,000 Beam Therapeutics shares in Q1 2021, an estimated $40.8M.
  • Alkeon Capital Management first reported a position in Beam Therapeutics in Q1 2020 and held it in 4 quarters.
  • Alkeon Capital Management's Beam Therapeutics position peaked at $40.8M in Q4 2020.
  • 209 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2021.

Based on Alkeon Capital Management's 13F filing for Q1 2021, filed 17 May 2021.